Abstract:e14006 Background: Radiation necrosis (RN) is post-radiation complication that leads to increased permeability and disruption of the blood brain barrier (BBB). This in turn leads to a pro-inflammatory state and an increased production of vascular-endothelial growth factor (VEGF). Bevacizumab is a monoclonal antibody against VEGF and is a potential treatment for RN. The objective of the study is to assess effectiveness of bevacizumab (BEV) for the treatment of brain RN in adults. Methods: Retrospective chart review of 22 patients with various solid malignancies including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), metastatic melanoma and breast cancer with clinical or radiographic diagnosis of RN seen at Memorial Cancer Institute (MCI) in a 3-year period, from January 1 st , 2019 to January 1 st , 2023. Radiation doses ranged from 18-24 Gy (single fraction) or 24-27 Gy (3-fraction) for radiosurgery and 30-37.5 Gy for whole brain radiotherapy. Patients were identified that developed RN and VEGF inhibitors were subsequently given to assess effectiveness in the treatment of the condition. We evaluated the dose, frequency, number of treatments received, adverse effects and therapeutic benefits of BEV. Therapeutic benefit was defined as patients that received bevacizumab had a radiological and clinical improvement of the RN (clinical benefit). Brain imaging with MRI or PET/CT scan was completed both pre and post treatment to evaluate efficacy of treatment. Patients were initially given 4 cycles with a subsequent 4 more cycles if it was beneficial and tolerated treatment. Results: 22 patients were included in the study, 9 were males (41%) and median age 66 (range 31-81). 91% (20/22) had a diagnosis of lung cancer. 1 patient had a diagnosis of SCLC, while 19 were diagnosed with NSCLC. The study had a good representation of different races including Non-Hispanic Whites 7 (32%), Hispanics 10 (45%), Blacks 13% (3) and Asians 10% (2). Over 95% (21/22) of patients achieved a clinical benefit, while one patient did not (5%). Patients experienced improvement in cognitive function, headaches, dizziness, weakness, and other symptoms with BEV. MRIs showed improvement in edema and a reduction/stabilization of brain lesions. The most frequent dosing regimen used was BEV 10 mg/kg every two weeks. The median number of cycles given was 4 cycles (1-12). The most common adverse events were hypertension, minor nose bleeding, an occasional protein found in urine. There were no severe AEs or discontinuation of therapy with bevacizumab. Conclusions: This study demonstrated treatment with BEV 10 mg/kg every two weeks for a total of 12 cycles is well tolerated and has potential clinical benefit in RN in lung cancer patients with CNS metastasis. The therapeutic effects of VEGF inhibitors were seen in our small population study but warrants further investigation in a larger population study.

Reducing Intratumour Acute Hypoxia Through Bevacizumab Treatment, Referring to the Response of Quiescent Tumour Cells and Metastatic Potential.

Bevacizumab for the Treatment of Gammaknife Radiosurgery-Induced Brain Radiation Necrosis

Significance of Manipulating Tumour Hypoxia and Radiation Dose Rate in Terms of Local Tumour Response and Lung Metastatic Potential, Referring to the Response of Quiescent Cell Populations

Outcomes with bevacizumab for radiation induced-brain necrosis.

Effect of bevacizumab on angiogenesis and related cytokines in mice with malignant pleural effusion

Long-Term Relief of Cerebral Radiation Necrosis Treated with Low-Dose Bevacizumab - a Report of 2 Cases

Bevacizumab reduces cerebral radiation necrosis due to stereotactic radiotherapy in non-small cell lung cancer patients with brain metastases: an inverse probability of treatment weighting analysis

Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab.

Ncmp-14. Radiographic Response To Bevacizumab In Treating Radiation Necrosis And Associated Edema In Brain Tumors

Bevacizumab Promotes Active Biological Behaviors Of Human Umbilical Vein Endothelial Cells By Activating Tgf Beta 1 Pathways Via Off-Vegf Signaling

Efficacy of Bevacizumab monotherapy on radiation-induced brian necrosis

A Study on the Evaluation Method and Recent Clinical Efficacy of Bevacizumab on the Treatment of Radiation Cerebral Necrosis

Tumor Angiogenic And Hypoxic Profiles Predict Radiographic Response And Survival In Malignant Astrocytoma Patients Treated With Bevacizumab And Irinotecan

Brain radiation necrosis treated with bevacizumab in a patient with advanced squamous cell lung carcinoma: A case report

Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab

Monitoring tumour microenvironment changes during anti-angiogenesis therapy using functional MRI

Experimental study of vascular normalization window for tumor induced by bevacizumab and efficacy of bevacizumab plus paclitaxel in lung cancer-bearing mice

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET

Reversal of Cerebral Radiation Necrosis with Bevacizumab Treatment in 17 Chinese Patients

The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma.

Acquired-resistance of Bevacizumab Treatment for Radiation Brain Necrosis: a Case Report